AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) ~~Substituted 9a-N-{N'-[4-(sulfonyl)phenylcarbamoyl]} derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro- 9a-aza-9a-homoerythronolide A~~ A compound of ~~the general~~ formula 1,



1

wherein R represents H or cladinosyl moiety, and R^1 represents chloro, amino, phenylamino, 2-pyridylamino, 3,4-dimethyl-5-isoxazolylamino or 5-methyl-3-isoxazolylamino group, or a pharmacetically acceptable salt thereof.

2. (currently amended) A ~~substance~~ compound according to claim 1, characterized in that R^1 represents chloro group and R represents cladinosyl moiety.

3. (currently amended) A ~~substance~~ compound according to claim 1 characterized in that R^1 represents chloro group, and R represents H.

4. (currently amended) A compound ~~Substance~~ according to claim 1 where R^1 represents amino group, and R represents cladinosyl moiety.

5. (currently amended) A ~~substance~~ compound according to claim 1, characterized in that R^1 represents phenylamino group, and R represents cladinosyl group.

6. (currently amended) A ~~substance~~ compound according to claim 1, characterized in that R^1 represents 2-pyridylamino group, and R represents cladinosyl group.

7. (currently amended) A ~~substance~~ compound according to claim 1, characterized in that R^1 represents 3,4-dimethyl-5-isoxazolyl group, and R represents cladinosyl moiety.

8. (currently amended) A ~~substance~~ compound according to claim 1, characterized in that R^1 represents 5-methyl-3-isoxazolylamino group, and R represents cladinosyl group.

9. (currently amended) A ~~substance~~ compound according to claim 1, characterized in that R^1 represents amino group and R represents H.

10. (currently amended) A ~~substance~~ compound according to claim 1, characterized in that R^1 represents phenylamino group, and R represents H.

11. (currently amended) A ~~substance~~ compound according to claim 1, characterized in that R^1 represents 2-pyridylamino group, and R represents H.

12. (currently amended) A ~~substance~~ compound according to claim 1, characterized in that R^1 represents 3,4-dimethyl-5-isoxazolylamino group, and R represents H.

13. (currently amended) A ~~substance~~ compound according to claim 1, characterized in that R^1 represents 5-methyl-3-isoxazolylamino group and R represents H.

14. (currently amended) A process for the preparation of ~~substituted 9a-N-{N'-[4-(sulfonyl)phenyl carbamoyl]} derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythronolide A~~ a compound of ~~the general~~ formula 1,



1

wherein R^1 represents amino, phenylamino, 2-pyridylamnio, 3,4-dimethyl-5-isoxazolylamino or 5-methyl-3-isoxazolylamino group and R represents H or cladinosyl group, comprising reacting ~~9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A or 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythronolide A~~ a compound of ~~general~~ formula 2



2

wherein R represents H or cladinosyl group, with 4-(chlorosulfonyl)phenyl isocyanate formula 3,



3

to form a compound of formula 1 wherein R is H or cladinosyl group and R^1 is chloro; reacting a compound of formula 1 wherein R is H or cladinosyl group and R^1 is chloro with ammonia or amine of general formula **4**,

$$R^2\text{-}NH_2$$

4

wherein R^2 represents H, phenyl, 2-pyridyl, 3,4-dimethyl-5-isoxazolyl or 5-methyl-3-isoxazolyl group, in toluene, xylene or some other aprotic solvent, at a temperature 0-110°C to form a compound of formula 1 wherein R is H or cladinosyl and R^1 is amino, phenylamino, 2-pyridylamino, 3,4-dimethyl-5-isozazolylamino or 5-methyl-3-ixozazolylamino.

15. (original) Pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antibacterially effective amount of the substances according to claim 1.

16. cancelled

17. (previously presented) A method for inhibiting bacterial growth in vitro on a surface or in a substance comprising applying to said surface or substance a bactericially effective amount of a compound according to claim 1.

18. (previously presented) The method of claim 17 wherein the surface is selected from the group consisting of a wall, a room, and a medical instrument.

19. (previously presented) The method of claim 17 wherein the substance is selected from the group of wall coatings and wooden coatings.

20. (currently amended) A process for the preparation of ~~substituted 9a-N-{N'-[4-(sulfonyl)phenyl carbamoyl]} derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythronolide A~~ a compound of ~~the general~~ formula 1,



1

wherein R^1 represents chloro and R represents H or cladinosyl group, comprising reacting ~~9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A or 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythronolide A~~ a compound of ~~general~~ formula 2



2

wherein R represents H or cladinosyl group with 4-(chlorosulfonyl)phenyl isocyanate formula 3,



3

to form a compound of formula 1 wherein R is H or cladinosyl and R^1 is chloro.

21. (currently amended) A compound ~~Substituted 9a-N-[N'-[4-(sulfonyl)phenylcarbamoyl]] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythronolide A~~ of ~~the~~ general formula 1,



1

wherein R represents H or cladinosyl moiety, and R^1 represents chloro, amino, phenylamino, 2-pyridylamino, 3,4-dimethyl-5-isoxazolylamino or 5-methyl-3-isoxazolylamino group.